p14 ARF/p16 Inhibitors
The chemical class of p14 ARF/p16 inhibitors comprises a spectrum of compounds that modulate the activity of cyclin-dependent kinases (CDKs), influencing the intricate regulatory network governing the tumor suppressor proteins p14 ARF and p16. These inhibitors play a pivotal role in disrupting the cell cycle and activating the p14 ARF/p16 checkpoint as a safeguard mechanism against uncontrolled cell proliferation. Palbociclib, PD0332991 (Ribociclib), and Abemaciclib are specific inhibitors of CDK4/6. Indirectly, these compounds disrupt the cell cycle by preventing the phosphorylation of retinoblastoma protein, leading to the activation of p14 ARF/p16 as a cell cycle checkpoint. Their selectivity for CDK4/6 highlights their specificity in influencing the regulatory machinery governing p14 ARF/p16. Broad-spectrum CDK inhibitors such as Flavopiridol and Dinaciclib inhibit multiple CDKs, including CDK4 and CDK6. By broadly targeting CDKs, these compounds disrupt the cell cycle and activate p14 ARF/p16, representing indirect inhibitors that affect the regulatory networks governing these tumor suppressors.
Roscovitine and JNJ-7706621 selectively inhibit CDK1 and CDK2, contributing to the activation of p14 ARF/p16 as cell cycle regulators. Their specificity highlights the intricate control of cell cycle progression and the significance of these CDKs in the modulation of p14 ARF/p16 activity. SNS-032, AZD5438, AT7519, R547, and PHA-793887 target a variety of CDKs, including CDK2, CDK4, and CDK6. Through their multi-CDK inhibitory activity, these compounds disrupt the cell cycle, leading to the activation of p14 ARF/p16 as a cell cycle checkpoint. Their broad influence underscores the complexity of the regulatory networks controlling p14 ARF/p16. In summary, the chemical class of p14 ARF/p16 inhibitors encompasses compounds that selectively or broadly inhibit CDKs, providing researchers with valuable tools to unravel the intricate mechanisms governing the activity of these crucial tumor suppressor proteins. The specificity of these inhibitors in targeting CDKs highlights their potential in modulating the delicate balance between cell proliferation and arrest mediated by p14 ARF/p16.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), indirectly modulating p14 ARF/p16. By inhibiting CDK4/6, Palbociclib disrupts the cell cycle, leading to reduced phosphorylation of retinoblastoma protein and subsequent activation of p14 ARF/p16 as a cell cycle checkpoint. Palbociclib represents an indirect inhibitor by targeting the regulatory machinery governing p14 ARF/p16 activity. | ||||||
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine Methanesulfonate | 1231930-82-7 | sc-496536 | 2.5 mg | $398.00 | ||
Abemaciclib is a potent inhibitor of CDK4/6, indirectly affecting p14 ARF/p16. By blocking CDK4/6, Abemaciclib impedes the cell cycle, leading to the activation of p14 ARF/p16 as a safeguard mechanism. This compound represents an indirect inhibitor by altering the regulatory networks governing p14 ARF/p16 activity. | ||||||
Flavopiridol Hydrochloride | 131740-09-5 | sc-207687 | 10 mg | $317.00 | ||
Flavopiridol is a broad-spectrum CDK inhibitor that indirectly modulates p14 ARF/p16. Through the inhibition of multiple CDKs, including CDK4 and CDK6, Flavopiridol disrupts the cell cycle, resulting in the activation of p14 ARF/p16 as a cell cycle checkpoint. This compound serves as an indirect inhibitor by broadly influencing the regulatory mechanisms governing p14 ARF/p16 activity. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent inhibitor of CDK1, CDK2, CDK5, and CDK9, indirectly affecting p14 ARF/p16. By broadly inhibiting CDKs, Dinaciclib disrupts the cell cycle, leading to the activation of p14 ARF/p16 as a cell cycle checkpoint. This compound represents an indirect inhibitor by broadly influencing the regulatory networks governing p14 ARF/p16 activity. | ||||||
Aurora Kinase/Cdk Inhibitor | 443797-96-4 | sc-203829 | 5 mg | $440.00 | ||
JNJ-7706621 is a dual CDK1/2 inhibitor, indirectly modulating p14 ARF/p16. By inhibiting CDK1 and CDK2, JNJ-7706621 disrupts the cell cycle, leading to the activation of p14 ARF/p16 as a cell cycle checkpoint. This compound serves as an indirect inhibitor by specifically targeting the regulatory machinery governing p14 ARF/p16 activity. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a selective inhibitor of CDK2, CDK7, and CDK9, indirectly affecting p14 ARF/p16. By inhibiting CDK2, SNS-032 disrupts the cell cycle, leading to the activation of p14 ARF/p16 as a cell cycle checkpoint. This compound represents an indirect inhibitor by specifically targeting the regulatory machinery governing p14 ARF/p16 activity. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 is a potent inhibitor of CDK1, CDK2, and CDK9, indirectly modulating p14 ARF/p16. By inhibiting CDK1, CDK2, and CDK9, AZD5438 disrupts the cell cycle, leading to the activation of p14 ARF/p16 as a cell cycle checkpoint. This compound serves as an indirect inhibitor by specifically targeting the regulatory machinery governing p14 ARF/p16 activity. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
AT7519 is a multi-CDK inhibitor that indirectly modulates p14 ARF/p16. By inhibiting CDKs, including CDK1, CDK2, CDK4, and CDK9, AT7519 disrupts the cell cycle, leading to the activation of p14 ARF/p16 as a cell cycle checkpoint. This compound represents an indirect inhibitor by broadly influencing the regulatory networks governing p14 ARF/p16 activity. | ||||||
R547 | 741713-40-6 | sc-364596 sc-364596A | 2 mg 5 mg | $375.00 $395.00 | ||
R547 is a selective inhibitor of CDK1, CDK2, and CDK4, indirectly affecting p14 ARF/p16. By inhibiting CDK1, CDK2, and CDK4, R547 disrupts the cell cycle, leading to the activation of p14 ARF/p16 as a cell cycle checkpoint. This compound serves as an indirect inhibitor by specifically targeting the regulatory machinery governing p14 ARF/p16 activity. | ||||||
PHA-793887 | 718630-59-2 | sc-364580 sc-364580A | 5 mg 10 mg | $189.00 $432.00 | ||
PHA-793887 is a potent inhibitor of CDK2, CDK4, and CDK6, indirectly modulating p14 ARF/p16. By inhibiting CDK2, CDK4, and CDK6, PHA-793887 disrupts the cell cycle, leading to the activation of p14 ARF/p16 as a cell cycle checkpoint. This compound represents an indirect inhibitor by specifically targeting the regulatory machinery governing p14 ARF/p16 activity. | ||||||